KIMS Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹872 Cr
verified against source
Revenue YoY
26.6%
reported change
EBITDA
₹194 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
KIMS reported 26.6% YoY revenue growth to INR 872 crore in Q1 FY26, driven by expansion across 25 centers with 8,000 beds. However, EBITDA margin compressed 390bps YoY to 22.7% due to losses from 5 new hospitals totaling INR 21 crore. The company commissioned ~800-bed Bangalore facilities and 120-bed Kolar unit, though faced 1-2 month delays from licensing. New unit losses are expected at INR 8-10 crore for Q2 (Maharashtra) and INR 10-15 crore for Bangalore (from Q3). Management guided FY26 margin range of 22-25%, with break-even expected within 12 months for Bangalore units at 30-40% occupancy. Nasik ramp-up was slow due to insurance/tPA delays, expected resolution in 3-6 months. O&M model hospitals (Sangli, Gur) are breakeven at INR 17-18 crore monthly revenue each. Competitive intensity noted in Telangana cluster, though no doctor attrition observed. Company ARPOB target of INR 50,000-55,000 over 2-3 years as Bangalore and Maharashtra units ramp. Key risk: insurance empanelment timelines (9-12 months typical) impacting revenue acceleration in new markets.
Colored figures show movement against the previous available record.
Guidance to track
- Margins expected in the 22-25% band for FY26, factoring in continued losses from new units (Bangalore, Maharashtra, Kerala) that will normalize over the next 12-18 months.
- Bangalore's 800-bed facilities (starting August-September) expected to become EBITDA neutral within 12 months of full operations, targeting 30-40% occupancy for break-even.
- Insurance and CGHS empanelments for Nasik hospital expected to be completed within 3-6 months, which should significantly accelerate revenue ramp from current ₹7 crore monthly cash business.
- Total EBITDA drag from new hospitals (Nasik, Tane, Kolar, Bangalore) estimated at ₹20-30 crore for FY26, with losses normalizing by Q2 FY27 for Maharashtra/Kerala and Q2 FY27 for Bangalore.
Risks flagged
- Nasik hospital ramp-up has been slow due to delayed insurance and corporate empanelment (accounts for 60% of volumes in Maharashtra cluster). Similar 9-12 month delays expected for Bangalore launch. Patients are choosing alternative hospitals rather than navigate cumbersome reimbursement processes.
- Nasik has 2-3 specialties still pending doctor onboarding, contingent on insurance empanelment completion. This creates a chicken-and-egg problem where insurance is needed to attract specialists, but specialists are needed to qualify for insurance.
- Company is in aggressive expansion mode with 5 new hospitals simultaneously ramping. EBITDA margin compressed to 22.7% vs 26.6% year-ago. Management deflected when asked for peak revenue potential and steady-state ROC targets by cluster, providing only directional guidance.
- AP cluster margins impacted in Q1 due to doctor onboarding costs at Kolar (commissioned July 1) and renovation delays at QNR acquired hospital. Renovation completion and subsequent ramp-up delayed into Q2-Q3.
Key quotes
- We are exploring more opportunities but the focus area and the clusters remain the same. More work in Karnataka, Kerala, Maharashtra and obviously a lot of greenfield brownfield edition in Telangana and AP. But our intent is to first stabilize a lot of the greenfield hospitals that got commissioned this year or will get commissioned this year.
- There's no capex commitment from our side on these O&M assets. We have full control over the P&L, the hospital operations, the clinical talent hiring, all of that is under the scope of KIMS. We manage the entire hospital for the promoters and we take a certain share of the revenue.
- I think anywhere in the 22 to 25% range is what we're looking at [for FY26 margins]. Beyond Q2 of next financial year, we have no greenfield assets that are getting commissioned. So we don't see these losses continuing beyond up until FY28-29 when we look at more green hospitals that come.
Research modules